Ligand Pharmaceuticals
LGND
227 hedge funds and large institutions have $2.35B invested in Ligand Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 56 increasing their positions, 107 reducing their positions, and 47 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
3% more capital invested
Capital invested by funds: $2.27B → $2.35B (+$77.9M)
6% less funds holding
Funds holding: 242 → 227 (-15)
26% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 47
44.6% less ownership
Funds ownership: 137.46% → 92.86% (-45%)
48% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 107
50% less call options, than puts
Call options by funds: $54.2M | Put options by funds: $108M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24.3M |
| 2 |
Millennium Management
New York
|
+$19.6M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
+$17.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.99M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$8.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$145M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$114M |
| 3 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$108M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$62.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$58M |
LGND Hedge Fund Activity: Q1 2021 in Review
227 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2021, worth a combined $2.35B — up 3.4% from $2.27B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of LGND and 35 opened new positions — a net loss of 12 holders — while 107 trimmed existing stakes and 56 added.
The largest buyer was BlackRock, adding an estimated $24.3M. The largest seller was Wasatch Advisors, cutting an estimated $145M.
- 227 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2021, down from 242 in Q4 2020.
- Funds reported $2.35B of Ligand Pharmaceuticals stock for Q1 2021, up 3.4% quarter-over-quarter.
- 35 funds opened new Ligand Pharmaceuticals positions in Q1 2021 and 47 closed out, a net change of -12 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2021 was BlackRock, an estimated $24.3M added.
- The largest Ligand Pharmaceuticals seller in Q1 2021 was Wasatch Advisors, an estimated $145M sold.
Based on aggregated 13F filings for Q1 2021.